On February 23, 2026 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA and PD-1 antibodies to treat cancer. Genprex maintains an exclusive license to these patents. The granting of these patents in key markets will strengthen Genprex’s intellectual property portfolio, providing further protection for various therapeutic combinations, including the Acclaim-3 clinical trial for the treatment of small cell lung cancer using REQORSA in combination with PD-L1 antibodies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The recent decisions by the Japanese Patent Office and European Patent Office to grant patents for our REQORSA gene therapy in combination with immunotherapies represent further validation for our innovative approach to cancer treatment," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. "These patents will strengthen our global intellectual property portfolio, providing protection for therapeutic combinations, including our ongoing Acclaim-3 clinical trial."
These patents build upon Genprex’s existing intellectual property framework. The Company already holds granted patents for the use of REQORSA in combination with PD-L1 antibodies in the U.S. and Korea, with a pending grant in Australia. Genprex also holds granted patents for the combination of REQORSA and PD-1 antibodies in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe. The Japanese and European patents will further solidify the global intellectual property landscape surrounding Genprex’s lead drug candidate in oncology.
About Acclaim-3
Acclaim-3 is a Phase 1/2 clinical trial evaluating the combination of REQORSA and Genentech’s Tecentriq (atezolizumab) as maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC) who are candidates for maintenance therapy after receiving Tecentriq and chemotherapy as standard of care initial treatment. In this study, patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.
The Phase 2 expansion study follows the successful completion of the Phase 1 dose escalation portion of the study, which showed REQORSA was generally well tolerated. There were no dose limiting toxicities, and in Acclaim-3, the Phase 2 patients are receiving the same dose of REQORSA as patients in the Phase 2 portion of Acclaim-1.
The Phase 2 expansion portion is expected to enroll approximately 50 patients. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. Genprex’s team plans to conduct an interim analysis after the 25th patient enrolled and treated reaches 18 weeks of follow up. The Company expects to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the first half of 2026 and expects the interim analysis in the second half of 2026. The Acclaim-3 clinical trial is supported by FDA Fast Track Designation and Orphan Drug Designation.
(Press release, Genprex, FEB 23, 2026, View Source [SID1234662851])